Novartis Ag (NVS) Shares Declined While Grimes & Company INC Increased Its Stake

April 17, 2018 - By Robert Reynolds

Novartis AG (NYSE:NVS) Corporate Logo

In 2017Q4 Securities and Exchange form is reported Grimes & Company Inc’s stake in Novartis Ag (NVS) which was upped by 160.59%. 50,821 shares were bought by Grimes & Company Inc as the company’s stock declined 4.22% with the market. The major pharmaceuticals company at the end of 2017Q4 was priced at $6.92 million. It’s up from 31,647 at the end of the previous reported quarter. Now it had 82,468 shares held by the institutional investor . For a total of 24,078 shares it reduced its holding in Spdr Barclays High Yield Bond (JNK) by 1.35 million shares in the quarter, and has cut its stake in Michael Kors Holdings Ltd. (NYSE:KORS).

Novartis AG (NYSE:NVS) Ratings Coverage

In total 4 analysts cover Novartis AG Common Stock (NYSE:NVS). “Buy” rating has 0, “Sell” are 2, while 2 are “Hold”. 0 are bullish. With $100 highest and $91 lowest [Target] Novartis AG Common Stock has $99 average [Target] or 21.97% above the current ($81.17) price. 5 are the (NYSE:NVS)’s analyst reports since October 23, 2017 according to StockzIntelligence Inc. On Friday, February 2 the firm has “Hold” rating by Cowen & Co given. On Wednesday, October 25 the firm earned “Sell” rating by Barclays Capital. The stock rating was maintained by Leerink Swann with “Market Perform” on Monday, October 23. On Wednesday, December 6 the firm has “Sell” rating given by Bank of America. On Thursday, January 25 the company was maintained by Leerink Swann.

Novartis AG (NYSE:NVS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: